NCT03238248View on ClinicalTrials.gov

Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

August 7, 2017

Primary Completion Date

September 30, 2022

Study Completion Date

November 27, 2023

Conditions
Myelodysplastic SyndromesMyeloproliferative Neoplasm
Interventions
DRUG

Azacitidine Subcutaneous Injection or Intravenous Infusion

75 mg/m2

DRUG

Pevonedistat Infusion

20 mg/m2

PROCEDURE

Bone Marrow Biopsy & Aspirate

Removal of a small piece of bone and bone marrow by inserting a needle into hip bone.

Trial Locations (5)

10065

Memorial Sloan-Kettering, New York

14642

University of Rochester Medical Center, Rochester

33136

University of Miami Miller School of Medicine, Miami

37232

Vanderbilt-Ingram Cancer Center, Nashville

66205

University of Kansas Cancer Center, Westwood

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT03238248 - Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors | Biotech Hunter | Biotech Hunter